2. European Organisation for Research and Treatment of Cancer (EORTC) http://groups.eortc.be/qol/quality-life (last accessed April 2013)
3. Breast Cancer Org. Living with Metastatic Disease: http://www.breastcancer.org/symptoms/types/recur_metast/livi... (Last accessed April 2013)
4. Kaufman P, Awada A, Twelves C et al. A Phase III, open-label, randomised, multicenter study of eribulinmesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Presented at 2012 CTRC-AACR San Antonio Breast Cancer Symposium. Abstract No. S6-6
5. Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulinmonotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. The Lancet. 2011; 377: 914 -923
6. Montazeri A et al. Quality of life in patients with breast cancer before and after diagnosis: an eighteen months follow up study. BMC Cancer. 2008. 3:330
7. World Health Organization. Atlas of Health in Europe. 2003. World Health Organization, Regional Office of Europe, Copenhagen, Denmark.
8. Cancer Research UK. Breast cancer incidence statistics. http://www.cancerresearchuk.org/cancer-info/cancerstats/type... [http://www.cancerresearchuk.org/cancer-info/cancerstats/type... ] (last accessed April 2013)
Fecha de preparación: mayo de 2013
Código de trabajo: Halaven-UK0142d
CONTACTO: Consultas sobre medios de comunicación: Media Enquiries: EisaiEurope Limited: Charlotte Andrews / Cressida Robson, +44-(0)7947-231513,+44-(0)790-831-4155, charlotte_andrews@eisai.net /cresida_robson@eisai.net. Tonic Life Communications: Siobhan Reilly / AprilKenneally, +44 (0)207-798-9999 / +44-(0)784-047-3199, +44-(0)207-798 9263 /+44-(0)788-561-4274, siobhan.reilly@toniclc.com /april.kenneally@toniclc.com
